The share of Indian drugs from the beginning of 2024 was about 4% of the Ukrainian pharma market, said Dr. R.U.P. Menon, president of the Indian Pharmaceutical Manufacturer’s Association (IPMA).
“India’s share in the first quarter of 2024 was about 4%, India is in the seventh place of the ranking,” he told Interfax-Ukraine.
Menon stressed that despite the stabilization of the pharma market since the beginning of 2024, “the sale of hospital drugs has decreased as there is still a lot of humanitarian aid in hospitals.”
At the same time, commenting on the situation with the logistics of pharma products from India to Ukraine under war conditions, Menon noted that currently the delivery route from India to Ukraine is complicated, as there is no possibility of direct air and sea delivery during martial law.
“The delivery is done through European ports and from there by road to Ukraine. Logistics from India takes a lot of time and it is expensive,” he stated.
However, Menon added that major international Indian pharma companies continue to operate in Ukraine through their local warehouses and supply medicines to leading Ukrainian distributors. Also, Indian pharmaceutical manufacturers continue to participate in government procurement, in particular, of drugs for the treatment of HIV/AIDS, tuberculosis and cancer.
According to him, in the retail segment there is still demand for Indian drugs for older age groups, stress management and sedative drugs.
Menon emphasized that all IPMA member companies have been contributing to Ukraine’s victory and helping Ukrainians since the first days of the full-scale war.
In particular, Indian pharmaceutical companies have provided about $16.6 million worth of pharmaceutical products as humanitarian aid during the full-scale war.
Meanwhile, in the first days after the missile attack on the Okhmatdet NDSB in Kiev, IPMA joined the aid and made a charitable contribution of half a million hryvnias to the hospital’s account.
“All members of our Association since the beginning of the war have not hesitated to mobilize to help Ukraine, donate and donate necessary medicines, material and financial resources to both Ukraine and non-governmental organizations, support Ukrainian citizens forced to leave their homes,” Menon said.
In addition, IPMA joined the initiative of the President of Ukraine Volodymyr Zelensky – UNITED24 and transferred to a special account of the National Bank to support the AFU half a million hryvnias.
IPMA unites companies that meet international standards FDA (USA), Health Canada (Canada), MHRA (UK), EMA (EU), MSS (South Africa), TGA (Australia), WHO GMP (WHO), GMP (Ukraine) and have representative offices in Ukraine. Indian Pharmaceutical Manufacturers Association (IPMA) represents the interests of leading Indian companies – manufacturers of pharmaceutical products in the Ukrainian market, contributes to the provision of quality and safe, effective and affordable medicines to the population of Ukraine.
Today the permanent members of IPMA are international companies Abryl Pharm LLC, Dia Pharma Limited, Dr.Reddy’s, Euro Lifecare Ltd, Hetero Labs Limited, M.Biotech Limited, Macleods Pharmaceutical Limited LLC, Mega Lifesciences LLC, Sun Pharma, Zandra Life Sciences PVT. LTD.
Indian Prime Minister Narendra Modi, during his visit to Kiev, intends to discuss with President Volodymyr Zelensky the possibilities of a peaceful end to the Russian-Ukrainian war.
“I look forward to continuing previous discussions with Zelensky on strengthening bilateral cooperation and sharing views on a peaceful resolution of the ongoing conflict in Ukraine,” Modi said in a statement released by his office on Wednesday.
The Indian prime minister will visit Ukraine on August 23 and meet with President Zelensky.
Earlier, the Indian Foreign Ministry emphasized that this is a “historic visit as it is the first time an Indian prime minister will visit Ukraine in more than 30 years of diplomatic relations.”
Indian drugs, Ukrainian pharma market
